Stocktoria
Relay Therapeutics, Inc. RLAY
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-07-16
Relay Therapeutics, Inc. statistics & valuation
Market cap$4.0B
P / B7.1×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1971.6% | -3722.1% | -1460.1% | -21670.9% | -12040.2% |
| Net margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% |
| FCF margin | -1536.1% | -2509.5% | -1191.7% | -17273.9% | -2571.0% |
| Return on assets | -44.5% | -38.8% | -40.5% | -26.4% | -36.1% |
| Return on equity | -48.8% | -43.4% | -45.5% | -30.6% | -40.5% |
| Current ratio | 22.61 | 15.95 | 25.44 | 16.00 | 40.14 |
| Revenue growth | 53.4% | -60.8% | 1749.8% | -54.4% | -96.3% |
Source: SEC EDGAR filings · CIK 0001812364 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.